Best Seo Company in Chennai - Apple Infoway Pvt Ltd
Apple Infoway Pvt Ltd is a reputed professional best SEO company in Chennai, Nowadays If you're planning to start a business whether it is a small or a big business you should establish your presence in internet, To start a business in this new generation doing SEO activities is a crucial one. SEO is widely used for to generate your business leads and conversion.
Since we have an own digital marketing institute for training, we make our students to work for our client's projects so that's the reason how we can give our service at this low amount, In quality wise we offers best service by providing complete knownledge on onpage and offpage seo optimization techniques, and we takes short time to complete our client projects since we have an huge number of people those who works for SEO.
TYPES OF SEO SERVICES
ONPAGE Optimization
OFFPAGE Optimization
ONPAGE OPTIMIZATION :
On page Optimization (Process) refers to all measures that can be taken directly within the website in order to improve its position in the search rankings of the website. Examples of this include measures to optimize the content or improve the meta description and title tags best SEO company in chennai .
Apple Infoways Pvt Ltd SEO analysts are strong in ON page activities. Our SEO ON page activities consist of Keyword Analysis & Research, Meta tag Optimizations, Robots, Site map integration, URL Optmization, Error Code Optimization, Analytiss and much more.
OFF PAGE OPTIMIZATION :
Off-page Optimization SEO activities is as important as the on-page SEO. Once you are done with your on page SEO, you must pay attention to the SEO Off-page optimization for better results in the search engine rankings. Apple Infoways Pvt Ltd SEO analysts are strong in Link building activities SEO company in chennai. Our SEO off page activities consist of article submission, blog posting and commenting, infographic submission, business listing, forum submission, video sharing, image sharing, ppt sharing, profile creation, guest posting, Q and A submission, bookmarking, classified submission and more.
ADVANTAGES & BENEFITS OF SEO :
Drive quality visitors to your website and increase sales dramatically Lower customer acquisition cost in comparison to other advertising and marketing channels Generate new sales leads Build brand awareness.
MUMBAI HEAD OFFICE ADDRESS
Apartment No.304 A Wing, Shiva Shakthi chs ltd, JP Road, Near Apna Bazar, Andheri(West),Mumbai - 400058. Maharashtra.
DELHI BRANCH OFFICE ADDRESS
No:224,Anarkali Bazar, Jhandewalan Extension, New Delhi-110055
Want to add a caption to this image? Click the Settings icon.
Tuesday, August 6, 2019
Jakavi 10mg(Ruxolitinib)
Jakavi 10mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production. Jakavi 10mg tablets is prescription drug provided under supervision of doctors or pharmacists
INDICATION
Jakavi 10mg is indicated for the treatment in patients with intermediate and high-risk myelofibrosis.
DOSAGE
Myelofibrosis :
Kinase inhibitor uses for treatment of patients with intermediate or high-risk myelofibrosis, involving mainly myelofibrosis, post-PolycythemiaVera myelofibrosis and post-essential thrombocythemia myelofibrosis
Starting recommended doses for myelofibrosis
If Platelet count >200 x10^9/L the dose given is 20 mg PO BID
If Platelet count 100-200 x10^9/L the dose given is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the dose given is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Polycythemia Vera
The recommended dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.
MECHANISM
Ruxolitinib is also knowns kinase inhibitor which is discriminating for the Janus analogue Kinases (JAK) 1 and 2. These kinases are required for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis.
The communicate process involves signal transducers and transcription activators (STAT) that modulate gene expression. Patients having myelofibrosis consist of abnormal JAK1 and JAK2 activity, Therefore Ruxolitinib function to regulate this.
PHARMACOKINETICS
Fast absorption and not affected by food maximum plasma level is 1.5 hours.
volume of distribution is 76.6 L plasma protein binding Jakavi 10mg tablets metabolized by CYP3A4 Jakavi 10mg tablets price in india eliminated via urine 74% and unchanged drug is <1% and through urine 22%,<1 % as unchanged drug
PRECAUTION
Treatment with Jakavi 10mg can resultedin thrombocytopenia, Anemia and neutropenia. Control thrombocytopenia by decreasing the dose or temporarily interfere with Jakavi 10mg tablets. Platelet transfusions may be necessary.
Risk of infection occurs by delay initiate treatment with Jakavi 10mg tablets price in india until active severe infection have resolved. Tuberculosis infection has been reported in patients receiving Jakavi 10mg. Observe patients receiving Jakavi 10mg tabletsfor signs and symptoms of active tuberculosis and manage promptly.
Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 10mg treatment. If PML is suspected, stop Jakavi 10mg and evaluate
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with Jakavi 10mg. Perform periodic skin examinations.
DRUG INTERACTION
Concomitant use with fluconazole doses greater than 200mg daily may increase Ruxolitinib exposure leads to increase the risks of exposure related adverse reaction.
Interaction of Jakavi 10mg tabletswith strong CYP3A4 inhibitors will increases Ruxolitinib exposure.
If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose. Avoid taking double the dose.
Pomahope 1mg is a Glenmark Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide.
Pomahope 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;
Immuno modulatory
Anti-angiogenesis
Anti-neoplastic Pomahope 1mg price in india is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment.
This may lead to severe liver injury. Pomahope 1mg capsule is involved in the treatment for regression & unmanageable multiple myeloma. Pomahope 1mg is used in the patients who are failing to response for Lenalidomide treatment. Pomahope 1mg is used in combination with dexamethasone.
INDICATION
The major therapeutic indication of Pomahope 1mg capsule is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomahope 1mgomide. Pomahope 1mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
DOSAGE & ADMINISTRATION
The prescribed dose of Pomahope in multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles. Pomahope 1mg should be concomitant with dexamethasone. Pomahope 1mg Capsules should be taken with or without food.
During hematological toxicities:
Neutropenia:
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomahope therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomahope3mg daily.
Thrombocytopenia:
Platelets count <25,000/mcL: postpone the Pomahope treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomahope Pomahope 1mg with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomahope by 50%
In renal impairment:
Initial dose of Pomahope is 3mg
In hepatic impairment:
Mild to moderate condition, an initial dose of Pomahope is 3mg; in severe condition, the initial dose of Pomahope is 2mg.
WORK AS
Pomahope 1mg exhibits various activities like;
Anti-neoplastic activity:
Prohibits proliferation
Promote apoptosis of hematopoietic cancer cells
Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Immuno modulatory:
Boosted the T-cells & natural killer cell mediate immunity.
The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Anti-angiogenesis:
Interfere with formation of new vessels and leads to inhibit the cell division.
WARNING
There are two major worsening condition may occur during the treatment using with Pomahope 1mg.
Embryo fetal damage : Pomahope 1mg Capsules are contraindicated to pregnancy period.
During the treatment, patients avoid to becoming pregnant.
Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism :
Patient who are receiving Pomahope 1mg Capsules price in india have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke.
This type of condition should be treated by initiating prophylactic anti-thrombotic drugs.
The patients who are acquiring this condition then thromboprophylaxis should be provided.
DRUG INTERACTION
Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4.
The concomitant use of Pomahope 1mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomahope leads to higher extent of adverse effects associated with Pomalid
In this condition, reduce the dose of Pomahope 1mg capsule and recommended.
CONTRAINDICATION
Pomahope 1mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomahope 1mg is X.
SIDE EFFECTS
More common effects of Pomahope 1mg :
If taken during pregnancy, Severe life-threatening human birth defects
Fatigue
Weakness
Low white blood cell count
Anemia
Constipation
Nausea
Diarrhea
Shortness of breath
Upper respiratory infections
Back pain
Fever.
Less common effects of Pomahope 1mg
Neuropathy
Dizziness
Confusion.
CONTACT US :
Phone Number:
+91-9987711567
Email ID:
applepharmaceutical@gmail.com
Address:
Apartment No.304 A Wing,
Shiva Shakthi chs ltd,
JP Road, Near Apna Bazar,
Andheri(West),
Mumbai - 400058.
Maharashtra.
Pomacel 2mg is a Glenmark Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide. Pomacel 2mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomacel 2mg is like thalidomide & Lenalidomidewith related to decreased rate of serum aminotransferase elevations during treatment. This may lead to severe liver injury.
INDICATION
The major therapeutic indication of Pomacel 2mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomacel 2mgomide. Pomacel 2mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
DOSAGE & ADMINISTRATION
The prescribed dose of Pomacelin multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles. Pomacel 2mg should be concomitant with dexamethasone. Pomacel 2mg Capsules should be taken with or without food. During hematological toxicities: Neutropenia; ANC (absolute neutrophils count) <500/mcl: Postpone the Pomaceltherapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomacel 3mg daily.
WORK AS
Pomacel 2mg exhibits various activities like; Anti-neoplastic activity: Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
WARNING
There are two major worsening condition may occur during the treatment using with Pomacel 2mg.
Embryo fetal damage :
Pomacel 2mg Capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
DRUG INTERACTION
Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomacel 2mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomacelleads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomacel 2mg and recommended.
SIDE EFFECTS
More common effects of Pomacel 2mg : If taken during pregnancy, Severe life-threatening human birth defects Fatigue Weakness Low white blood cell count Anemia Constipation Nausea Diarrhea Shortness of breath Upper respiratory infections Back pain Fever.
Pomyelo 2mg is a product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide. Pomyelo 2mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomyelo 2mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may lead to severe liver injury. Pomyelo 2mg is involved in the treatment for regression & unmanageable multiple myeloma. Pomyelo 2mg is used in the patients who are failing to response for Lenalidomide treatment. Pomyelo 2mg is used in combination with dexamethasone.
INDICATION
The major therapeutic indication of Pomyelo 2mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomyelo 2mg. Pomyelo 2mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
DOSAGE & ADMINISTRATION
Pomyelo 2mg should be concomitant with dexamethasone. Pomyelo 2mg capsules should be taken with or without food. During hematological toxicities:
Neutropenia:
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomyelo therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomyelo3mg daily.
Thrombocytopenia:
Platelets count <25,000/mcL: postpone the Pomyelo treatment & follow the CBC >50,000/mcL: continue 3mg of Pomyelo Pomyelo 2mg with potent CYP1A2 inhibitor: During this combination reduce the dose of Pomyelo by 50%
WARNING
There are two major worsening condition may occur during the treatment using with Pomyelo 2mg.
Embryo fetal damage:
Pomyelo 2mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Anti-angiogenesis:
Interfere with formation of new vessels and leads to inhibit the cell division.
SIDE EFFECTS
More common effects :
If taken during pregnancy, Severe life-threatening human birth defects Fatigue Weakness Low white blood cell count Anemia Constipation Nausea
Friday, July 19, 2019
Pomalid 1mg capsules (pomalidomide) - Buy Pomalid 1mg capsules Online at best Price in India -apple pharmaceuticals
Pomalid (pomalidomide) 1mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 1mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury.Pomalid(pomalyst) 1mg is involved in the treatment for regression & unmanageable multiple myeloma.Pomalid(pomalidomide) 1mg is used in the patients who are failing to response for Lenalidomide treatment.Pomalid(pomalyst) 1mg is used in combination with dexamethasone.
INDICATION
The major therapeutic indication of Pomalid(pomalidomide) 1mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid(pomalyst) 1mg Pomalid(pomalidomide) 1mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.
Thrombocytopenia :
Platelets count <25,000/mcL: postpone the Pomalid capsule treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid capsule Pomalid(pomalidomide) 1mg with potent CYP1A2 inhibitor : During this combination reduce the dose of Pomalid by 50%
Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg.
POMALID 1MG WORKS
Pomalid(pomalyst) 1mg exhibits various activities like; Anti-neoplastic activity
Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis Immuno modulatory
Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes. Anti-angiogenesis
Interfere with formation of new vessels and leads to inhibit the cell division.
WARNING
There are two major worsening condition may occur during the treatment using with Pomalid(pomalidomide) 1mg. Embryo fetal damage
Pomalid(pomalyst) 1mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy. Venous & arterial thromboembolism
Patient who are receiving Pomalid(pomalidomide)1mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided
DRUG INTERACTION
Pomalidomide(pomalyst) metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid 1mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid capsule leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid(pomalidomide) 1mg and recommended.
Lenangio 25mg is belongs to anticancer medication which contains Lenalidomide as an active substance which belongs to thalidomide analogue. Lenangio 25mg is used to the disease condition by combining with dexamethasone. Lenangio 25mg consist of some other pharmacological activities like immuno modulatory & anti-angiogenesis. Lenangio 25mg is a prescription drug that can only use under the supervision of medical oncologist.
INDICATION
The indications of Lenangio 25mg are; Lenangio combination with dexamethasone is indicated to treat the patients suffered from multiple myeloma Lenangio is indicated for the patients having transfusion-dependent anemia because of intermediate 1 risk myelodysplastic syndrome along with deletion 5q cytogenetic abnormality without or without addition cytogenetic abnormalities Lenangio is used to treat the patients with mantle cell lymphoma in which its used whose the disease was relapsed or progressed after two before treatment, especially the disease not response with the bortezomib therapy.
The adult usual dose of Lenangio 25mg in myelodysplastic syndromes is 10mg and administrated once a day. For renal damaged patients; CrCl >60ml/min In Patients should not needed dosage adjustment of Lenangio CrCl 30 to 60ml/min In Patients, 5mg of Lenangio should administer orally as once daily CrCl <30ml/min In Patient, 2.5mg of Lenangio should be given orally as a once daily. Dosage variation; Thrombocytopenia: Drops to <50000/mcL, treatment should be interrupted. Back to > or equal to 50000/mcL, follow the Lenangio of 5mg per day. Neutropenia; Drops to <500/mcL, treatment should be delayed. Back to > or equal to 500/mcL, treatment should be follow to 5mg per day. Multiple myeloma; In this disease, concomitant use of dexamethasone with Lenangio. The regular dose of Lenangio is 25mg should be given as once in a day on day 1 to 21. The dose of dexamethasone; Dexamethasone 40mg should be continued on day 1 to 4, 9 to 12 & 17 to 20 of each period of 28-day cycles. Patient with greater than 75 years, dexamethasone 20mg should be prescribed on day 1, 8, 15, & 22. Mantle cell lymphoma; The usual dose of Lenangio for this disease is 25mg should be given orally as once daily. For renal damaged patients; CrCl 30 to 60ml/min in patient, Lenangio 10mg should be given as once daily. CrCl <30ml/min in patients, Lenangio 15mg should be used for q48hr. Pediatrics; The safety & efficiency of Lenalidomide has not been described in pediatric patients with age of <18 years.
MECHANISM
Lenangio 25mg involves in the prudence of tumor and factor alpha arrangement, that reinforcement the T-cells and leads to lessening plasma levels of cytokines vascular endothelial growth factor and fundamental fibroblast growth factor. Lenangio 25mg is moreover engaged with the stave off angiogenesis. Lenalidomide is furthermore authorized G1 cell cycle capture and apoptosis of ruinous cells.
PHARMACOKINETICS
Absorption:
Absorbed rapidly with peak plasma concentration is between 0.625 and 1.5 hrs. combining with food will not change the prolong of absorption but dose decrease in Cmax.
Distribution:
Bounding of plasma protein is 30%
Metabolism:
Mainly metabolized in two metabolites is hydroxy-lenalidomide and N-acetyl-lenalidomide.
Excretion:
Primarily eliminated in renal route and the dose excreted via urine 90% and feces 4% and half-life is 3hrs.
DRUG INTERACTION
Interaction of Lenangio 25mg with digoxin leads to increased concentration of digoxin causes increased risk of adverse effects related to digoxin. Interaction of Lenangio 25mg with Erythropoietic agents, cause to produced rises in risk of thrombosis. Discuss with the patients prior to starting this combination treatment. Interaction of Lenangio 25mg with warfarin, will produce increased exposure of hemorrhage disorders. check the INR value & prothrombin time.
CONTRAINDICATION
When pregnancy period the drug is contraindicated The patients are contraindicated to hypersensitivity reaction and the Lenangio 25mg component.
OVER DOSAGE
Over dosage of Lenangio 25mg will cause neutropenia & thrombocytopenia as mainly common side effects. Give the patient general supportive treatment. check the blood cells counts regularly during the treatment.
MISSED DOSE
The missed dose of Lenangio 25mg should be avoided. If missed dose founded, then patients should be consulting with doctor specialized in oncologist Regulate the usual dosing schedule.
SIDE EFFECTS
Second primary malignancies Hepatotoxicity , Hypersensitivity reactions, Thyroid dysfunction, Fetal toxicity, Hematological toxicity, Tumor lysis syndrome, Tumor flare reactions, Increase of mortality rate. Common side effects; Diabetes mellitus, Rash, Insomnia, Depression, Deep vein thrombosis, Myocardial infraction, Renal failure, Squamous cell carcinoma, Basal cell carcinoma, Fatigue, Asthenia, Pyrexia, Pain, Diarrhea, Dyspepsia, Bone pain, Neck pain, Respiratory infections, UTI, Influenza, Sepsis, Headache, Anemia, Loss of appetite, Hypokalemia, Hyperglycemia, Hypocalcaemia, Dehydration, Gout.
WARNING
The some of the common life-threatening condition like : Venous & arterial thromboembolism Blood clotting effects Embryo fetal damage Hypersensitivity reactions Hematological disorders For all these conditions, some supportive measures should be used and provide safety measures.
Lenangio 10mg is belongs to anticancer medication which contains Lenalidomide as an active substance which belongs to thalidomide analogue. Lenangio 10mg is used to the disease condition by combining with dexamethasone. Lenangio 10mg consist of some other pharmacological activities like immuno modulatory & anti-angiogenesis. Lenangio 10mg is a prescription drug that can only use under the supervision of medical oncologist.
INDICATION
The indications of Lenangio 10mg are; Lenangio combination with dexamethasone is indicated to treat the patients suffered from multiple myeloma Lenangio is indicated for the patients having transfusion-dependent anemia because of intermediate 1 risk myelodysplastic syndrome along with deletion 5q cytogenetic abnormality without or without addition cytogenetic abnormalities Lenangio is used to treat the patients with mantle cell lymphoma in which its used whose the disease was relapsed or progressed after two before treatment, especially the disease not response with the bortezomib therapy.
The adult usual dose of Lenangio 10mg in myelodysplastic syndromes is 10mg and administrated once a day. For renal damaged patients; CrCl >60ml/min In Patients should not needed dosage adjustment of Lenangio CrCl 30 to 60ml/min In Patients, 5mg of Lenangio should administer orally as once daily CrCl <30ml/min In Patient, 2.5mg of Lenangio should be given orally as a once daily. Dosage variation;
Thrombocytopenia:
Drops to <50000/mcL, treatment should be interrupted. Back to > or equal to 50000/mcL, follow the Lenangio of 5mg per day. Neutropenia; Drops to <500/mcL, treatment should be delayed. Back to > or equal to 500/mcL, treatment should be follow to 5mg per day. Multiple myeloma; In this disease, concomitant use of dexamethasone with Lenangio. The regular dose of Lenangio is 25mg should be given as once in a day on day 1 to 21. The dose of dexamethasone; Dexamethasone 40mg should be continued on day 1 to 4, 9 to 12 & 17 to 20 of each period of 28-day cycles. Patient with greater than 75 years, dexamethasone 20mg should be prescribed on day 1, 8, 15, & 22. Mantle cell lymphoma; The usual dose of Lenangio for this disease is 25mg should be given orally as once daily. For renal damaged patients; CrCl 30 to 60ml/min in patient, Lenangio 10mg should be given as once daily. CrCl <30ml/min in patients, Lenangio 15mg should be used for q48hr. Pediatrics; The safety & efficiency of Lenalidomide has not been described in pediatric patients with age of <18 years.
MECHANISM
Lenangio 10mg involves in the prudence of tumor and factor alpha arrangement, that reinforcement the T-cells and leads to lessening plasma levels of cytokines vascular endothelial growth factor and fundamental fibroblast growth factor. Lenangio 10mg is moreover engaged with the stave off angiogenesis. Lenalidomide is furthermore authorize G1 cell cycle capture and apoptosis of ruinous cells.
PHARMACOKINETICS
Absorption:
Absorbed rapidly with peak plasma concentration is between 0.625 and 1.5 hrs. combining with food will not change the prolong of absorption but dose decrease in Cmax.
Distribution:
Bounding of plasma protein is 30%
Metabolism:
Mainly metabolized in two metabolites is hydroxy-lenalidomide and N-acetyl-lenalidomide.
Excretion:
Primarily eliminated in renal route and the dose excreted via urine 90% and feces 4% and half-life is 3hrs.
DRUG INTERACTION
Interaction of Lenangio 10mg with digoxin leads to increased concentration of digoxin causes increased risk of adverse effects related to digoxin. Interaction of Lenangio 10mg with Erythropoietic agents, cause to produced rises in risk of thrombosis. Discuss with the patients prior to starting this combination treatment. Interaction of Lenangio 10mg with warfarin, will produce increased exposure of hemorrhage disorders. check the INR value & prothrombin time.
CONTRAINDICATION
When pregnancy period the drug is contraindicated The patients are contraindicated to hypersensitivity reaction and the Lenangio 10mg component.
OVER DOSAGE
Over dosage of Lenangio 10mg will cause neutropenia & thrombocytopenia as mainly common side effects. Give the patient general supportive treatment. check the blood cells counts regularly during the treatment.
MISSED DOSE
The missed dose of Lenangio 10mg should be avoided. If missed dose founded, then patients should be consulting with doctor specialized in oncologist Regulate the usual dosing schedule.
SIDE EFFECTS
Second primary malignancies Hepatotoxicity , Hypersensitivity reactions, Thyroid dysfunction, Fetal toxicity, Hematological toxicity, Tumor lysis syndrome, Tumor flare reactions, Increase of mortality rate. Common side effects; Diabetes mellitus, Rash, Insomnia, Depression, Deep vein thrombosis, Myocardial infraction, Renal failure, Squamous cell carcinoma, Basal cell carcinoma, Fatigue, Asthenia, Pyrexia, Pain, Diarrhea, Dyspepsia, Bone pain, Neck pain, Respiratory infections, UTI, Influenza, Sepsis, Headache, Anemia, Loss of appetite, Hypokalemia, Hyperglycemia, Hypocalcaemia, Dehydration, Gout.
WARNING
The some of the common life-threatening condition like : Venous & arterial thromboembolism Blood clotting effects Embryo fetal damage Hypersensitivity reactions Hematological disorders For all these conditions, some supportive measures should be used and provide safety measures.
Lenangio 5mg is belongs to anticancer medication which contains Lenalidomide as an active substance which belongs to thalidomide analogue. Lenangio 5mg is used to the disease condition by combining with dexamethasone. Lenangio 5mg consist of some other pharmacological activities like immuno modulatory & anti-angiogenesis. Lenangio 5mg is a prescription drug that can only use under the supervision of medical oncologist.
INDICATION
The indications of Lenangio 5mg are; Lenangio combination with dexamethasone is indicated to treat the patients suffered from multiple myeloma Lenangio is indicated for the patients having transfusion-dependent anemia because of intermediate 1 risk myelodysplastic syndrome along with deletion 5q cytogenetic abnormality without or without addition cytogenetic abnormalities Lenangio is used to treat the patients with mantle cell lymphoma in which its used whose the disease was relapsed or progressed after two before treatment, especially the disease not response with the bortezomib therapy.
The adult usual dose of Lenangio 5mg capsule in myelodysplastic syndromes is 10mg and administrated once a day. For renal damaged patients; CrCl >60ml/min In Patients should not needed dosage adjustment of Lenangio CrCl 30 to 60ml/min In Patients, 5mg of Lenangio should administer orally as once daily CrCl <30ml/min In Patient, 2.5mg of Lenangio should be given orally as a once daily. Dosage variation;
Thrombocytopenia:
Drops to <50000/mcL, treatment should be interrupted. Back to > or equal to 50000/mcL, follow the Lenangio of 5mg per day. Neutropenia; Drops to <500/mcL, treatment should be delayed. Back to > or equal to 500/mcL, treatment should be follow to 5mg per day. Multiple myeloma; In this disease, concomitant use of dexamethasone with Lenangio. The regular dose of Lenangio is 25mg should be given as once in a day on day 1 to 21. The dose of dexamethasone; Dexamethasone 40mg should be continued on day 1 to 4, 9 to 12 & 17 to 20 of each period of 28-day cycles. Patient with greater than 75 years, dexamethasone 20mg should be prescribed on day 1, 8, 15, & 22. Mantle cell lymphoma; The usual dose of Lenangio for this disease is 25mg should be given orally as once daily. For renal damaged patients; CrCl 30 to 60ml/min in patient, Lenangio 10mg should be given as once daily. CrCl <30ml/min in patients, Lenangio 15mg should be used for q48hr. Pediatrics; The safety & efficiency of Lenalidomide has not been described in pediatric patients with age of <18 years.
MECHANISM
Lenangio 5mg involves in the prudence of tumor and factor alpha arrangement, that reinforcement the T-cells and leads to lessening plasma levels of cytokines vascular endothelial growth factor and fundamental fibroblast growth factor. Lenangio 5mg is moreover engaged with the stave off angiogenesis. Lenalidomide is furthermore authorized G1 cell cycle capture and apoptosis of ruinous cells.
PHARMACOKINETICS
Absorption:
Absorbed rapidly with peak plasma concentration is between 0.625 and 1.5 hrs. combining with food will not change the prolong of absorption but dose decrease in Cmax.
Distribution:
Bounding of plasma protein is 30%
Metabolism:
Mainly metabolized in two metabolites is hydroxy-lenalidomide and N-acetyl-lenalidomide.
Excretion:
Primarily eliminated in renal route and the dose excreted via urine 90% and feces 4% and half-life is 3hrs
DRUG INTERACTION
Interaction of Lenangio 5mg with digoxin leads to increased concentration of digoxin causes increased risk of adverse effects related to digoxin. Interaction of Lenangio 5mg with Erythropoietic agents, cause to produced rises in risk of thrombosis. Discuss with the patients prior to starting this combination treatment. Interaction of Lenangio 5mg with warfarin, will produce increased exposure of hemorrhage disorders. check the INR value & prothrombin time.
CONTRAINDICATION
When pregnancy period the drug is contraindicated The patients are contraindicated to hypersensitivity reaction and the Lenangio 5mg component.
OVER DOSAGE
Over dosage of Lenangio 5mg will cause neutropenia & thrombocytopenia as mainly common side effects. Give the patient general supportive treatment. check the blood cells counts regularly during the treatment.
MISSED DOSE
The missed dose of Lenangio 5mg should be avoided. If missed dose founded, then patients should be consulting with doctor specialized in oncologist Regulate the usual dosing schedule.
SIDE EFFECTS
Second primary malignancies Hepatotoxicity , Hypersensitivity reactions, Thyroid dysfunction, Fetal toxicity, Hematological toxicity, Tumor lysis syndrome, Tumor flare reactions, Increase of mortality rate. Common side effects; Diabetes mellitus, Rash, Insomnia, Depression, Deep vein thrombosis, Myocardial infraction, Renal failure, Squamous cell carcinoma, Basal cell carcinoma, Fatigue, Asthenia, Pyrexia, Pain, Diarrhea, Dyspepsia, Bone pain, Neck pain, Respiratory infections, UTI, Influenza, Sepsis, Headache, Anemia, Loss of appetite, Hypokalemia, Hyperglycemia, Hypocalcaemia, Dehydration, Gout.
WARNING
The some of the common life-threatening condition like : Venous & arterial thromboembolism Blood clotting effects Embryo fetal damage Hypersensitivity reactions Hematological disorders For all these conditions, some supportive measures should be used and provide safety measures.
Friday, July 12, 2019
POMALID 4mg
Pomalid (pomalidomide)4mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 4mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 4mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury.Pomalid 4mg is involved in the treatment for regression & unmanageable multiple myeloma.Pomalid(pomalidomide) 4mg is used in the patients who are failing to response for Lenalidomide treatment.Pomalid(pomalyst) 4mg is used in combination with dexamethasone.
INDICATION
The major therapeutic indication of Pomalid(pomalidomide) 4mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid 4mgomide. Pomalid 4mg capsule is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor. During hematological toxicities
Neutropenia :
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg capsule daily.
Thrombocytopenia :
Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid Pomalid(pomalidomide) 4mg with potent CYP1A2 inhibitor : During this combination reduce the dose of Pomalid by 50%
Mild to moderate condition, an initial dose of Pomalid is 3mg; in severe condition, the initial dose of Pomalid is 2mg. Pomalid(pomalidomide) 4mg WORKS
Pomalid 4mg exhibits various activities like; Anti-neoplastic activity
Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis Immuno modulatory
Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes. Anti-angiogenesis
Interfere with formation of new vessels and leads to inhibit the cell division.
WARNING
There are two major worsening condition may occur during the treatment using with Pomalid(pomalidomide) 4mg. Embryo fetal damage
Pomalid(pomalyst) 4mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy. Venous & arterial thromboembolism
Patient who are receiving Pomalid(pomalidomide) 4mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided
CONTRAINDICATION
Pomalid(pomalidomide) 4mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomalid 4mg is X.
DRUG INTERACTION
Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid 4mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid(pomalidomide) 4mg and recommended.
Pomalid 2mg
Pomalid(pomalidomide) 2mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 2mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 2mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury.Pomalid(pomalyst) 2mg is involved in the treatment for regression & unmanageable multiple myeloma.Pomalid(pomalidomide) 2mg is used in the patients who are failing to response for Lenalidomide treatment.Pomalid(pomalyst) 2mg is used in combination with dexamethasone.
INDICATION
The major therapeutic indication of Pomalid 2mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid(pomalyst) 2mg pomalidomide. Pomalid(pomalidomide) 2mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor. During hematological toxicities
Neutropenia :
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.
Thrombocytopenia :
Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid Pomalid(pomalidomide) 2mg with potent CYP1A2 inhibitor : During this combination reduce the dose of Pomalid(pomalyst) by 50%
Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg. Pomalid(pomalidomide) 2mg WORKS
Pomalid(pomalyst) 2mg exhibits various activities like; Anti-neoplastic activity
Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis Immuno modulatory
Prohibits proliferation Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes. Anti-angiogenesis
Prohibits proliferation Interfere with formation of new vessels and leads to inhibit the cell division.
WARNING
There are two major worsening condition may occur during the treatment using with Pomalid 2mg. Embryo fetal damage
Pomalid(pomalidomide) 2mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy. Venous & arterial thromboembolism
Patient who are receiving Pomalid(pomalidomide) 2mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided
DRUG INTERACTION
Pomalidomide? metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid(pomalidomide) 2mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid 2mg and recommended.
CONTRAINDICATION
Pomalid 2mg capsuel should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomalid(pomalyst) 2mg is X.
